David C. Dvorak Sells 1,040 Shares of Zimmer Biomet Holdings Inc (ZBH) Stock

Zimmer Biomet Holdings Inc (NYSE:ZBH) insider David C. Dvorak sold 1,040 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $121.63, for a total transaction of $126,495.20. Following the sale, the insider now owns 294,077 shares of the company’s stock, valued at $35,768,585.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) traded up 1.32% during trading on Thursday, hitting $121.85. 833,455 shares of the stock were exchanged. The firm has a 50 day moving average of $120.04 and a 200-day moving average of $114.18. The company has a market cap of $24.50 billion, a price-to-earnings ratio of 80.70 and a beta of 1.20. Zimmer Biomet Holdings Inc has a 12-month low of $95.63 and a 12-month high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Tuesday, January 31st. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.03. Zimmer Biomet Holdings had a return on equity of 16.66% and a net margin of 3.90%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter last year, the business posted $2.09 EPS. Zimmer Biomet Holdings’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, analysts forecast that Zimmer Biomet Holdings Inc will post $8.59 earnings per share for the current year.

Insider Buying and Selling by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

The business also recently announced a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date is Wednesday, March 29th. Zimmer Biomet Holdings’s payout ratio is presently 65.31%.

TRADEMARK VIOLATION NOTICE: “David C. Dvorak Sells 1,040 Shares of Zimmer Biomet Holdings Inc (ZBH) Stock” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2017/04/20/insider-selling-zimmer-biomet-holdings-inc-zbh-insider-sells-126495-20-in-stock-updated-updated.html.

Several research firms have recently commented on ZBH. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, April 4th. Royal Bank of Canada reissued a “buy” rating and issued a $133.00 price objective on shares of Zimmer Biomet Holdings in a research note on Tuesday, March 14th. Robert W. Baird reiterated an “outperform” rating and issued a $136.00 price target (up previously from $130.00) on shares of Zimmer Biomet Holdings in a research note on Wednesday, February 1st. Oppenheimer Holdings Inc. set a $132.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Wednesday, February 1st. Finally, Canaccord Genuity set a $144.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Tuesday, January 31st. One analyst has rated the stock with a sell rating, three have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $136.31.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Johnson Financial Group Inc. increased its position in shares of Zimmer Biomet Holdings by 17.4% in the fourth quarter. Johnson Financial Group Inc. now owns 977 shares of the medical equipment provider’s stock valued at $100,000 after buying an additional 145 shares during the last quarter. Independent Advisor Alliance bought a new position in shares of Zimmer Biomet Holdings during the fourth quarter valued at approximately $103,000. Parkside Financial Bank & Trust increased its position in shares of Zimmer Biomet Holdings by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 964 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 5 shares during the last quarter. Capital Guardian Trust Co. increased its position in shares of Zimmer Biomet Holdings by 52.1% in the fourth quarter. Capital Guardian Trust Co. now owns 1,229 shares of the medical equipment provider’s stock valued at $127,000 after buying an additional 421 shares during the last quarter. Finally, Acrospire Investment Management LLC bought a new position in shares of Zimmer Biomet Holdings during the third quarter valued at approximately $130,000. 86.62% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply